Landry John 4

4 · VAPOTHERM INC · Filed Feb 29, 2024

Insider Transaction Report

Form 4

Period: 2024-02-27

VAPOTHERM INCVAPO

Landry John

See Remarks

Transactions

Award
Stock Option (right to buy)
2024-02-27+2,150→ 2,150 total
Exercise: $0.92Exp: 2031-01-01→ Common Stock (2,150 underlying)
Award
Stock Option (right to buy)
2024-02-27+3,250→ 3,250 total
Exercise: $0.92Exp: 2030-01-01→ Common Stock (3,250 underlying)
Award
Stock Option (right to buy)
2024-02-27+3,503→ 3,503 total
Exercise: $0.92Exp: 2029-01-11→ Common Stock (3,503 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−9,943→ 0 total
Exercise: $97.28Exp: 2030-01-01→ Common Stock (9,943 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−2,150→ 0 total
Exercise: $214.88Exp: 2031-01-01→ Common Stock (2,150 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−3,503→ 0 total
Exercise: $137.20Exp: 2029-01-11→ Common Stock (3,503 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−3,250→ 0 total
Exercise: $97.28Exp: 2030-01-01→ Common Stock (3,250 underlying)
Award
Stock Option (right to buy)
2024-02-27+9,943→ 9,943 total
Exercise: $0.92Exp: 2030-01-01→ Common Stock (9,943 underlying)
Award
Stock Option (right to buy)
2024-02-27+6,625→ 6,625 total
Exercise: $0.92Exp: 2032-05-10→ Common Stock (6,625 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−3,062→ 0 total
Exercise: $165.68Exp: 2032-01-01→ Common Stock (3,062 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−6,625→ 0 total
Exercise: $25.28Exp: 2032-05-10→ Common Stock (6,625 underlying)
Award
Stock Option (right to buy)
2024-02-27+6,834→ 6,834 total
Exercise: $0.92Exp: 2033-01-02→ Common Stock (6,834 underlying)
Award
Stock Option (right to buy)
2024-02-27+3,062→ 3,062 total
Exercise: $0.92Exp: 2032-01-01→ Common Stock (3,062 underlying)
Disposition to Issuer
Stock Option (right to buy)
2024-02-27−6,834→ 0 total
Exercise: $21.60Exp: 2033-01-02→ Common Stock (6,834 underlying)

Holdings

Common Stock
(indirect: By IRA)
425
Common Stock
68,918
Common Stock
(indirect: By IRA)
1,693

Footnotes (8)

[F1]Includes 625 shares that were purchased under the Vapotherm, Inc. 2018 Employee Stock Purchase Plan, 23,845 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Vapotherm, Inc. Amended and Restated 2018 Equity Incentive Plan and 10,760 shares held by the reporting person's Roth IRA.
[F2]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
[F3]This option, which was previously subject to four-year vesting, is fully vested.
[F4]The transactions reported herein reflect a stock option repricing effective February 27, 2024 pursuant to which the exercise price of the repriced options was amended to reduce the exercise price to $0.915 per share, the closing price of the Issuer's common stock on February 27, 2024. There is no change to the expiration dates or the vesting schedule of the repriced options.
[F5]This option vested as to 25% of the underlying shares on January 1, 2022, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.
[F6]This option vested as to 25% of the underlying shares on January 1, 2023, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.
[F7]This option vested as to 25% of the underlying shares on January 1, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.
[F8]This option vested as to 25% of the underlying shares on January 2, 2024, and thereafter, as to the remaining 75% of underlying shares, in 36 monthly installments, provided that the Reporting Person continues to serve as an employee or other service provider to the Issuer on each vesting date and otherwise subject to the Issuer's applicable equity incentive plan.

Documents

1 file

4
primary_doc.xmlPrimary
PRIMARY DOCUMENT